Recently, a team from the University of Colorado used a NetMHCpan 4.0-based in silico prediction followed by in vitro biochemical validation strategy to identify the most frequent mutant EGFR-derived neoantigens bound by prevalent human leukocyte antigen (HLA) class I alleles in NSCLC patients [39]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.